APLIF News and Press, Appili Therapeutics Inc From 05/08/23

Funding will enable Appili to advance it’s Biodefense Vaccine Candidate ATI-1701 to IND NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “...

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will presen...

Accomplished biopharmaceutical executive brings more than 25 years of experience leading vaccine and antibody product development for infectious disease indications Dr. Nabors representing Appili at the World Vaccine Congress in Washington, D.C. Appili Therapeutics Inc. (TSX: AP...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectiou...

Appili Therapeutics press release ( OTCQB:APLIF ): Q3 GAAP EPS of -$0.06. As of December 31, 2022, the Company had cash of $1.4 million, For further details see: Appili Therapeutics GAAP EPS of -$0.06

Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal yea...

Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program. Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmace...

Appili Therapeutics ( OTCQB:APLIF ) said that it will get a patent from the U.S. Patent and Trademark Office (USPTO) for ATI-1501, a liquid oral reformulation of the antibiotic metronidazole. Metronidazole is used to treat parasitic and anaerobic bacterial infections. T...

Anticipated new patent strengthens ATI-1501’s potential position as a more convenient alternative treatment option for metronidazole prescriptions on the market. Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharma...

Appili Therapeutics ( OTCQX:APLIF ) has announced that the U.S. Department of Defense will provide at least $14M in funding over two years to fund the development of ATI-1701. ATI-1701 is a potential first-in-class vaccine candidate for the prevention of infection with aerosol...